Editas Medicine to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Editas Medicine (NASDAQ: EDIT), a gene editing company, has announced its participation in three major healthcare investor conferences in September 2025. The company will attend the Wells Fargo Healthcare Conference on September 3 in Boston, the Cantor Global Healthcare Conference on September 4 in New York featuring a fireside chat at 11:30 a.m. ET, and the Baird Global Healthcare Conference on September 9 in New York.

Live webcasts of available presentations can be accessed through the Investors section of Editas Medicine's website, with replays available for approximately 30 days after each event.

[]

News Market Reaction

-2.20%

1 alert

-2.20% News Effect

On the day this news was published, EDIT declined 2.20%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that management will participate in the following upcoming investor conferences in September:

• Wells Fargo Healthcare Conference
  Format: One-on-one Meetings
  Date: Wednesday, September 3
  Location: Boston, MA

• Cantor Global Healthcare Conference
  Format: Fireside Chat with Webcast and One-on-one Meetings
  Date: Thursday, September 4
  Time: 11:30 a.m. ET
  Location: New York, NY

• Baird Global Healthcare Conference.
  Format: Presentation and One-on-one Meetings
  Date: Tuesday, September 9
  Location: New York, NY
  

To access the live webcasts (where available) of Editas Medicine’s presentations, please visit the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following each event.

About Editas Medicine 
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com. 

Investor and Media Contacts: 
ir@editasmed.com 
media@editasmed.com

FAQ

When is Editas Medicine (EDIT) presenting at the Cantor Global Healthcare Conference 2025?

Editas Medicine will present in a fireside chat format on Thursday, September 4, 2025, at 11:30 a.m. ET in New York, NY.

How can investors access Editas Medicine's (EDIT) conference presentations?

Investors can access available live webcasts through the Investors section of Editas Medicine's website at www.editasmedicine.com. Archived replays will be available for approximately 30 days after each event.

Which investor conferences will Editas Medicine (EDIT) attend in September 2025?

Editas Medicine will attend three conferences: the Wells Fargo Healthcare Conference (Sept 3), Cantor Global Healthcare Conference (Sept 4), and Baird Global Healthcare Conference (Sept 9).

How long will Editas Medicine's (EDIT) conference presentation replays be available?

The archived replays of the conference presentations will be available for approximately 30 days following each event on the company's website.